OncoSenX is a late stage pre-clinical cancer company which focuses on genetic information to discover the next generation of cancer therapy. It targets solid tumors based on transcriptional activity using a lipid nanoparticle and plasmid DNA. The company offers a less invasive, more precise intervention approach.